This report aims to provide a comprehensive presentation of the global market for Biosimilars Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biosimilars Treatment. This report contains market size and forecasts of Biosimilars Treatment in global, including the following market information:
Global Biosimilars Treatment Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Biosimilars Treatment market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Recombinant Non ? Glycosylated Proteins Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Biosimilars Treatment include Bayer, Eli Lily, Inc., Pfizer, Inc., Sandoz International GmbH, Teva Pharmaceutical Industries Limited, Amgen Inc., Biocon, Dr. Reddy?s Laboratories and Roche Ltd., etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Biosimilars Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Biosimilars Treatment Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Biosimilars Treatment Market Segment Percentages, by Type, 2022 (%)
Recombinant Non ? Glycosylated Proteins
Recombinant Glycosylated Proteins
Recombinant Peptides
Global Biosimilars Treatment Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Biosimilars Treatment Market Segment Percentages, by Application, 2022 (%)
Oncology
Chronic and Autoimmune Disease
Blood Disorders
Growth Hormone Disease
Infectious Disease
Global Biosimilars Treatment Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Biosimilars Treatment Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Biosimilars Treatment revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Biosimilars Treatment revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Bayer
Eli Lily, Inc.
Pfizer, Inc.
Sandoz International GmbH
Teva Pharmaceutical Industries Limited
Amgen Inc.
Biocon
Dr. Reddy?s Laboratories
Roche Ltd.
Celltrion, Inc.
Samsung Bioepis
Outline of Major Chapters:
Chapter 1: Introduces the definition of Biosimilars Treatment, market overview.
Chapter 2: Global Biosimilars Treatment market size in revenue.
Chapter 3: Detailed analysis of Biosimilars Treatment company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Biosimilars Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Biosimilars Treatment Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Biosimilars Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Biosimilars Treatment Overall Market Size
2.1 Global Biosimilars Treatment Market Size: 2022 VS 2035
2.2 Global Biosimilars Treatment Market Size, Prospects & Forecasts: 2018-2035
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Biosimilars Treatment Players in Global Market
3.2 Top Global Biosimilars Treatment Companies Ranked by Revenue
3.3 Global Biosimilars Treatment Revenue by Companies
3.4 Top 3 and Top 5 Biosimilars Treatment Companies in Global Market, by Revenue in 2022
3.5 Global Companies Biosimilars Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Biosimilars Treatment Players in Global Market
3.6.1 List of Global Tier 1 Biosimilars Treatment Companies
3.6.2 List of Global Tier 2 and Tier 3 Biosimilars Treatment Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Biosimilars Treatment Market Size Markets, 2022 & 2035
4.1.2 Recombinant Non ? Glycosylated Proteins
4.1.3 Recombinant Glycosylated Proteins
4.1.4 Recombinant Peptides
4.2 By Type - Global Biosimilars Treatment Revenue & Forecasts
4.2.1 By Type - Global Biosimilars Treatment Revenue, 2018-2023
4.2.2 By Type - Global Biosimilars Treatment Revenue, 2024-2035
4.2.3 By Type - Global Biosimilars Treatment Revenue Market Share, 2018-2035
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Biosimilars Treatment Market Size, 2022 & 2035
5.1.2 Oncology
5.1.3 Chronic and Autoimmune Disease
5.1.4 Blood Disorders
5.1.5 Growth Hormone Disease
5.1.6 Infectious Disease
5.2 By Application - Global Biosimilars Treatment Revenue & Forecasts
5.2.1 By Application - Global Biosimilars Treatment Revenue, 2018-2023
5.2.2 By Application - Global Biosimilars Treatment Revenue, 2024-2035
5.2.3 By Application - Global Biosimilars Treatment Revenue Market Share, 2018-2035
6 Sights by Region
6.1 By Region - Global Biosimilars Treatment Market Size, 2022 & 2035
6.2 By Region - Global Biosimilars Treatment Revenue & Forecasts
6.2.1 By Region - Global Biosimilars Treatment Revenue, 2018-2023
6.2.2 By Region - Global Biosimilars Treatment Revenue, 2024-2035
6.2.3 By Region - Global Biosimilars Treatment Revenue Market Share, 2018-2035
6.3 North America
6.3.1 By Country - North America Biosimilars Treatment Revenue, 2018-2035
6.3.2 US Biosimilars Treatment Market Size, 2018-2035
6.3.3 Canada Biosimilars Treatment Market Size, 2018-2035
6.3.4 Mexico Biosimilars Treatment Market Size, 2018-2035
6.4 Europe
6.4.1 By Country - Europe Biosimilars Treatment Revenue, 2018-2035
6.4.2 Germany Biosimilars Treatment Market Size, 2018-2035
6.4.3 France Biosimilars Treatment Market Size, 2018-2035
6.4.4 U.K. Biosimilars Treatment Market Size, 2018-2035
6.4.5 Italy Biosimilars Treatment Market Size, 2018-2035
6.4.6 Russia Biosimilars Treatment Market Size, 2018-2035
6.4.7 Nordic Countries Biosimilars Treatment Market Size, 2018-2035
6.4.8 Benelux Biosimilars Treatment Market Size, 2018-2035
6.5 Asia
6.5.1 By Region - Asia Biosimilars Treatment Revenue, 2018-2035
6.5.2 China Biosimilars Treatment Market Size, 2018-2035
6.5.3 Japan Biosimilars Treatment Market Size, 2018-2035
6.5.4 South Korea Biosimilars Treatment Market Size, 2018-2035
6.5.5 Southeast Asia Biosimilars Treatment Market Size, 2018-2035
6.5.6 India Biosimilars Treatment Market Size, 2018-2035
6.6 South America
6.6.1 By Country - South America Biosimilars Treatment Revenue, 2018-2035
6.6.2 Brazil Biosimilars Treatment Market Size, 2018-2035
6.6.3 Argentina Biosimilars Treatment Market Size, 2018-2035
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Biosimilars Treatment Revenue, 2018-2035
6.7.2 Turkey Biosimilars Treatment Market Size, 2018-2035
6.7.3 Israel Biosimilars Treatment Market Size, 2018-2035
6.7.4 Saudi Arabia Biosimilars Treatment Market Size, 2018-2035
6.7.5 UAE Biosimilars Treatment Market Size, 2018-2035
7 Biosimilars Treatment Companies Profiles
7.1 Bayer
7.1.1 Bayer Company Summary
7.1.2 Bayer Business Overview
7.1.3 Bayer Biosimilars Treatment Major Product Offerings
7.1.4 Bayer Biosimilars Treatment Revenue in Global Market (2018-2023)
7.1.5 Bayer Key News & Latest Developments
7.2 Eli Lily, Inc.
7.2.1 Eli Lily, Inc. Company Summary
7.2.2 Eli Lily, Inc. Business Overview
7.2.3 Eli Lily, Inc. Biosimilars Treatment Major Product Offerings
7.2.4 Eli Lily, Inc. Biosimilars Treatment Revenue in Global Market (2018-2023)
7.2.5 Eli Lily, Inc. Key News & Latest Developments
7.3 Pfizer, Inc.
7.3.1 Pfizer, Inc. Company Summary
7.3.2 Pfizer, Inc. Business Overview
7.3.3 Pfizer, Inc. Biosimilars Treatment Major Product Offerings
7.3.4 Pfizer, Inc. Biosimilars Treatment Revenue in Global Market (2018-2023)
7.3.5 Pfizer, Inc. Key News & Latest Developments
7.4 Sandoz International GmbH
7.4.1 Sandoz International GmbH Company Summary
7.4.2 Sandoz International GmbH Business Overview
7.4.3 Sandoz International GmbH Biosimilars Treatment Major Product Offerings
7.4.4 Sandoz International GmbH Biosimilars Treatment Revenue in Global Market (2018-2023)
7.4.5 Sandoz International GmbH Key News & Latest Developments
7.5 Teva Pharmaceutical Industries Limited
7.5.1 Teva Pharmaceutical Industries Limited Company Summary
7.5.2 Teva Pharmaceutical Industries Limited Business Overview
7.5.3 Teva Pharmaceutical Industries Limited Biosimilars Treatment Major Product Offerings
7.5.4 Teva Pharmaceutical Industries Limited Biosimilars Treatment Revenue in Global Market (2018-2023)
7.5.5 Teva Pharmaceutical Industries Limited Key News & Latest Developments
7.6 Amgen Inc.
7.6.1 Amgen Inc. Company Summary
7.6.2 Amgen Inc. Business Overview
7.6.3 Amgen Inc. Biosimilars Treatment Major Product Offerings
7.6.4 Amgen Inc. Biosimilars Treatment Revenue in Global Market (2018-2023)
7.6.5 Amgen Inc. Key News & Latest Developments
7.7 Biocon
7.7.1 Biocon Company Summary
7.7.2 Biocon Business Overview
7.7.3 Biocon Biosimilars Treatment Major Product Offerings
7.7.4 Biocon Biosimilars Treatment Revenue in Global Market (2018-2023)
7.7.5 Biocon Key News & Latest Developments
7.8 Dr. Reddy?s Laboratories
7.8.1 Dr. Reddy?s Laboratories Company Summary
7.8.2 Dr. Reddy?s Laboratories Business Overview
7.8.3 Dr. Reddy?s Laboratories Biosimilars Treatment Major Product Offerings
7.8.4 Dr. Reddy?s Laboratories Biosimilars Treatment Revenue in Global Market (2018-2023)
7.8.5 Dr. Reddy?s Laboratories Key News & Latest Developments
7.9 Roche Ltd.
7.9.1 Roche Ltd. Company Summary
7.9.2 Roche Ltd. Business Overview
7.9.3 Roche Ltd. Biosimilars Treatment Major Product Offerings
7.9.4 Roche Ltd. Biosimilars Treatment Revenue in Global Market (2018-2023)
7.9.5 Roche Ltd. Key News & Latest Developments
7.10 Celltrion, Inc.
7.10.1 Celltrion, Inc. Company Summary
7.10.2 Celltrion, Inc. Business Overview
7.10.3 Celltrion, Inc. Biosimilars Treatment Major Product Offerings
7.10.4 Celltrion, Inc. Biosimilars Treatment Revenue in Global Market (2018-2023)
7.10.5 Celltrion, Inc. Key News & Latest Developments
7.11 Samsung Bioepis
7.11.1 Samsung Bioepis Company Summary
7.11.2 Samsung Bioepis Business Overview
7.11.3 Samsung Bioepis Biosimilars Treatment Major Product Offerings
7.11.4 Samsung Bioepis Biosimilars Treatment Revenue in Global Market (2018-2023)
7.11.5 Samsung Bioepis Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Biosimilars Treatment Market Opportunities & Trends in Global Market
Table 2. Biosimilars Treatment Market Drivers in Global Market
Table 3. Biosimilars Treatment Market Restraints in Global Market
Table 4. Key Players of Biosimilars Treatment in Global Market
Table 5. Top Biosimilars Treatment Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Biosimilars Treatment Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Biosimilars Treatment Revenue Share by Companies, 2018-2023
Table 8. Global Companies Biosimilars Treatment Product Type
Table 9. List of Global Tier 1 Biosimilars Treatment Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Biosimilars Treatment Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Biosimilars Treatment Revenue, (US$, Mn), 2022 & 2035
Table 12. By Type - Biosimilars Treatment Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Biosimilars Treatment Revenue in Global (US$, Mn), 2024-2035
Table 14. By Application ? Global Biosimilars Treatment Revenue, (US$, Mn), 2022 & 2035
Table 15. By Application - Biosimilars Treatment Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Biosimilars Treatment Revenue in Global (US$, Mn), 2024-2035
Table 17. By Region ? Global Biosimilars Treatment Revenue, (US$, Mn), 2022 & 2035
Table 18. By Region - Global Biosimilars Treatment Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Biosimilars Treatment Revenue (US$, Mn), 2024-2035
Table 20. By Country - North America Biosimilars Treatment Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Biosimilars Treatment Revenue, (US$, Mn), 2024-2035
Table 22. By Country - Europe Biosimilars Treatment Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Biosimilars Treatment Revenue, (US$, Mn), 2024-2035
Table 24. By Region - Asia Biosimilars Treatment Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Biosimilars Treatment Revenue, (US$, Mn), 2024-2035
Table 26. By Country - South America Biosimilars Treatment Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Biosimilars Treatment Revenue, (US$, Mn), 2024-2035
Table 28. By Country - Middle East & Africa Biosimilars Treatment Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Biosimilars Treatment Revenue, (US$, Mn), 2024-2035
Table 30. Bayer Company Summary
Table 31. Bayer Biosimilars Treatment Product Offerings
Table 32. Bayer Biosimilars Treatment Revenue (US$, Mn) & (2018-2023)
Table 33. Bayer Key News & Latest Developments
Table 34. Eli Lily, Inc. Company Summary
Table 35. Eli Lily, Inc. Biosimilars Treatment Product Offerings
Table 36. Eli Lily, Inc. Biosimilars Treatment Revenue (US$, Mn) & (2018-2023)
Table 37. Eli Lily, Inc. Key News & Latest Developments
Table 38. Pfizer, Inc. Company Summary
Table 39. Pfizer, Inc. Biosimilars Treatment Product Offerings
Table 40. Pfizer, Inc. Biosimilars Treatment Revenue (US$, Mn) & (2018-2023)
Table 41. Pfizer, Inc. Key News & Latest Developments
Table 42. Sandoz International GmbH Company Summary
Table 43. Sandoz International GmbH Biosimilars Treatment Product Offerings
Table 44. Sandoz International GmbH Biosimilars Treatment Revenue (US$, Mn) & (2018-2023)
Table 45. Sandoz International GmbH Key News & Latest Developments
Table 46. Teva Pharmaceutical Industries Limited Company Summary
Table 47. Teva Pharmaceutical Industries Limited Biosimilars Treatment Product Offerings
Table 48. Teva Pharmaceutical Industries Limited Biosimilars Treatment Revenue (US$, Mn) & (2018-2023)
Table 49. Teva Pharmaceutical Industries Limited Key News & Latest Developments
Table 50. Amgen Inc. Company Summary
Table 51. Amgen Inc. Biosimilars Treatment Product Offerings
Table 52. Amgen Inc. Biosimilars Treatment Revenue (US$, Mn) & (2018-2023)
Table 53. Amgen Inc. Key News & Latest Developments
Table 54. Biocon Company Summary
Table 55. Biocon Biosimilars Treatment Product Offerings
Table 56. Biocon Biosimilars Treatment Revenue (US$, Mn) & (2018-2023)
Table 57. Biocon Key News & Latest Developments
Table 58. Dr. Reddy?s Laboratories Company Summary
Table 59. Dr. Reddy?s Laboratories Biosimilars Treatment Product Offerings
Table 60. Dr. Reddy?s Laboratories Biosimilars Treatment Revenue (US$, Mn) & (2018-2023)
Table 61. Dr. Reddy?s Laboratories Key News & Latest Developments
Table 62. Roche Ltd. Company Summary
Table 63. Roche Ltd. Biosimilars Treatment Product Offerings
Table 64. Roche Ltd. Biosimilars Treatment Revenue (US$, Mn) & (2018-2023)
Table 65. Roche Ltd. Key News & Latest Developments
Table 66. Celltrion, Inc. Company Summary
Table 67. Celltrion, Inc. Biosimilars Treatment Product Offerings
Table 68. Celltrion, Inc. Biosimilars Treatment Revenue (US$, Mn) & (2018-2023)
Table 69. Celltrion, Inc. Key News & Latest Developments
Table 70. Samsung Bioepis Company Summary
Table 71. Samsung Bioepis Biosimilars Treatment Product Offerings
Table 72. Samsung Bioepis Biosimilars Treatment Revenue (US$, Mn) & (2018-2023)
Table 73. Samsung Bioepis Key News & Latest Developments
List of Figures
Figure 1. Biosimilars Treatment Segment by Type in 2022
Figure 2. Biosimilars Treatment Segment by Application in 2022
Figure 3. Global Biosimilars Treatment Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Biosimilars Treatment Market Size: 2022 VS 2035 (US$, Mn)
Figure 6. Global Biosimilars Treatment Revenue, 2018-2035 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Biosimilars Treatment Revenue in 2022
Figure 8. By Type - Global Biosimilars Treatment Revenue Market Share, 2018-2035
Figure 9. By Application - Global Biosimilars Treatment Revenue Market Share, 2018-2035
Figure 10. By Type - Global Biosimilars Treatment Revenue, (US$, Mn), 2022 & 2035
Figure 11. By Type - Global Biosimilars Treatment Revenue Market Share, 2018-2035
Figure 12. By Application - Global Biosimilars Treatment Revenue, (US$, Mn), 2022 & 2035
Figure 13. By Application - Global Biosimilars Treatment Revenue Market Share, 2018-2035
Figure 14. By Region - Global Biosimilars Treatment Revenue Market Share, 2018-2035
Figure 15. By Country - North America Biosimilars Treatment Revenue Market Share, 2018-2035
Figure 16. US Biosimilars Treatment Revenue, (US$, Mn), 2018-2035
Figure 17. Canada Biosimilars Treatment Revenue, (US$, Mn), 2018-2035
Figure 18. Mexico Biosimilars Treatment Revenue, (US$, Mn), 2018-2035
Figure 19. By Country - Europe Biosimilars Treatment Revenue Market Share, 2018-2035
Figure 20. Germany Biosimilars Treatment Revenue, (US$, Mn), 2018-2035
Figure 21. France Biosimilars Treatment Revenue, (US$, Mn), 2018-2035
Figure 22. U.K. Biosimilars Treatment Revenue, (US$, Mn), 2018-2035
Figure 23. Italy Biosimilars Treatment Revenue, (US$, Mn), 2018-2035
Figure 24. Russia Biosimilars Treatment Revenue, (US$, Mn), 2018-2035
Figure 25. Nordic Countries Biosimilars Treatment Revenue, (US$, Mn), 2018-2035
Figure 26. Benelux Biosimilars Treatment Revenue, (US$, Mn), 2018-2035
Figure 27. By Region - Asia Biosimilars Treatment Revenue Market Share, 2018-2035
Figure 28. China Biosimilars Treatment Revenue, (US$, Mn), 2018-2035
Figure 29. Japan Biosimilars Treatment Revenue, (US$, Mn), 2018-2035
Figure 30. South Korea Biosimilars Treatment Revenue, (US$, Mn), 2018-2035
Figure 31. Southeast Asia Biosimilars Treatment Revenue, (US$, Mn), 2018-2035
Figure 32. India Biosimilars Treatment Revenue, (US$, Mn), 2018-2035
Figure 33. By Country - South America Biosimilars Treatment Revenue Market Share, 2018-2035
Figure 34. Brazil Biosimilars Treatment Revenue, (US$, Mn), 2018-2035
Figure 35. Argentina Biosimilars Treatment Revenue, (US$, Mn), 2018-2035
Figure 36. By Country - Middle East & Africa Biosimilars Treatment Revenue Market Share, 2018-2035
Figure 37. Turkey Biosimilars Treatment Revenue, (US$, Mn), 2018-2035
Figure 38. Israel Biosimilars Treatment Revenue, (US$, Mn), 2018-2035
Figure 39. Saudi Arabia Biosimilars Treatment Revenue, (US$, Mn), 2018-2035
Figure 40. UAE Biosimilars Treatment Revenue, (US$, Mn), 2018-2035
Figure 41. Bayer Biosimilars Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Eli Lily, Inc. Biosimilars Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Pfizer, Inc. Biosimilars Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Sandoz International GmbH Biosimilars Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Teva Pharmaceutical Industries Limited Biosimilars Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Amgen Inc. Biosimilars Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Biocon Biosimilars Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Dr. Reddy?s Laboratories Biosimilars Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Roche Ltd. Biosimilars Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Celltrion, Inc. Biosimilars Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Samsung Bioepis Biosimilars Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
